Difference between revisions of "Breaking And Entering"

From LGPedia
Jump to: navigation, search
(wtf?)
Line 1: Line 1:
 
'''Breaking and Entering''' is the one-hundred and third video in the Lonelygirl15 video series.
 
'''Breaking and Entering''' is the one-hundred and third video in the Lonelygirl15 video series.
 +
 +
 +
 +
EPOGEN® is indicated for the treatment of anemia in patients with chronic renal failure on dialysis.Important Product Safety InformationEPOGEN® is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of seizures, thrombotic events, and other serious events. The target hemoglobin (Hb) should not exceed 12 g/dL. If the Hb increase exceeds 1.0 g/dL in any 2-week period, dose reductions are recommended. In a study with hemodialysis patients with clinically evident cardiac disease, where the target hematocrit (Hct) was 42% (Hb = 14 g/dL), an increased incidence of thrombotic events and mortality was seen. The reason for increased mortality observed in this study is unknown.Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias associated with neutralizing antibodies to erythropoietin, have been reported in patients treated with EPOGEN®. A sudden loss of response to EPOGEN®, accompanied by severe anemia and low reticulocyte count, should be evaluated. If anti-erythropoietin antibody-associated anemia is suspected, withhold EPOGEN® and other erythropoietic proteins. EPOGEN® should be permanently discontinued in patients with antibody-mediated anemia. Patients should not be switched to other erythropoietic proteins.The most commonly reported side effects in clinical trials were hypertension, headache, arthralgias, and nausea.

Revision as of 03:49, 22 December 2006

Breaking and Entering is the one-hundred and third video in the Lonelygirl15 video series.


EPOGEN® is indicated for the treatment of anemia in patients with chronic renal failure on dialysis.Important Product Safety InformationEPOGEN® is contraindicated in patients with uncontrolled hypertension. Erythropoietic therapies may increase the risk of seizures, thrombotic events, and other serious events. The target hemoglobin (Hb) should not exceed 12 g/dL. If the Hb increase exceeds 1.0 g/dL in any 2-week period, dose reductions are recommended. In a study with hemodialysis patients with clinically evident cardiac disease, where the target hematocrit (Hct) was 42% (Hb = 14 g/dL), an increased incidence of thrombotic events and mortality was seen. The reason for increased mortality observed in this study is unknown.Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias associated with neutralizing antibodies to erythropoietin, have been reported in patients treated with EPOGEN®. A sudden loss of response to EPOGEN®, accompanied by severe anemia and low reticulocyte count, should be evaluated. If anti-erythropoietin antibody-associated anemia is suspected, withhold EPOGEN® and other erythropoietic proteins. EPOGEN® should be permanently discontinued in patients with antibody-mediated anemia. Patients should not be switched to other erythropoietic proteins.The most commonly reported side effects in clinical trials were hypertension, headache, arthralgias, and nausea.